For the year ending 2025-12-31, GTBP had $2,861K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -28,354 |
| Stock based compensation | 432 |
| Loss on initial recognition of greenshoe rights liability | 28,736 |
| Change in fair value of greenshoe rights liability | -11,413 |
| Change in fair value of warrant liability | -241 |
| Gain on settlement of debt | 998 |
| Issuance of warrants for vrt waiver | 44 |
| Gain on extinguishment of debt | 200 |
| (increase) decrease in prepaid expenses and deferred offering costs | -377 |
| Increase (decrease) in accounts payable and accrued expenses | -1,297 |
| Net cash used in operating activities | -12,914 |
| Exercise of warrants and issuance of inducement warrants for cash, net | 5,496 |
| Proceeds from issuance of series l preferred stock and warrants, net | 10,508 |
| Payment of dividend on series l preferred stock | 229 |
| Net cash provided by financing activities | 15,775 |
| Net increase in cash and cash equivalents and restricted cash | 2,861 |
| Cash and cash equivalents and restricted cash at beginning of period | 4,044 |
| Cash and cash equivalents and restricted cash at end of period | 6,905 |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)